Skip to main content
OpenTrials
Completed

NCT Number: NCT02980692

Efficacy and Safety Study of SUNPG1623

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

SPARC Site 1

Middleburg Heights, Ohio, 44130, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has provided written informed consent
  • Subject is ≥ 18 years of age at time of Screening
  • Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
  • Subject has a negative evaluation for TB within 4 weeks before initiating IMP
  • Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis [CASPAR] criteria) with symptoms present for at least 6 months.
  • Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.

Exclusion criteria

  • Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition
  • Subject has an active infection or history of infections
  • Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease
  • Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus

Treatment and study plan

SUNPG1623 I

Drug

injection

SUNPG1623 II

Drug

injection

SUNPG1623 III

Drug

injection

SUNPG1623 IV

Drug

injection

Placebo

Drug

injection

Primary outcomes

  1. Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate

    Time frame: week 24

    The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Secondary outcomes

  1. Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate

    Time frame: week 52

    The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

  2. Proportion of Subjects Achieving American College of Rheumatology50 Response Rate

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

    The American College of Rheumatology50 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

  3. Proportion of Subjects Achieving American College of Rheumatology70 Response Rate

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52

    The American College of Rheumatology70 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

  4. Change From Baseline in Tender Joint Counts

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

  5. Change From Baseline in Tender Joint Counts

    Time frame: Week 52

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

  6. Change From Baseline in Swollen Joint Counts

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

  7. Change From Baseline in Swollen Joint Counts

    Time frame: Week 52

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

  8. Physician Global Assessment of Disease Activity Visual Analog Scale

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

  9. Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale

    Time frame: Week 52

    100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

  10. Patient's Global Assessment of Disease Activity

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20 and week 24

    100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

  11. Change From Baseline in Patient's Global Assessment of Disease Activity

    Time frame: Week 52

    100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

  12. Patient's Pain Assessment

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

  13. Change From Baseline in Patient's Pain Assessment

    Time frame: Week 52

    100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

  14. Health Assessment Questionnaire- Disability Index

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).

    The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

  15. Change From Baseline in Health Assessment Questionnaire- Disability Index

    Time frame: Week 52

    eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).

    The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

  16. Acute Phase C - Reactive Protein

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.

    CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation

  17. Acute Phase C - Reactive Protein

    Time frame: Week 52

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.

    CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation.

    Change from Baseline in C-Reactive Protein.

  18. Erythrocyte Sedimentation Rate

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

    An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

  19. Change From Baseline in Erythrocyte Sedimentation Rate

    Time frame: Week 52

    An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

  20. The Proportion of Subjects Who Require Adjustment of Background Therapy

    Time frame: Week 16

  21. Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52

    The Disease Activity Score 28-item C-Reactive Protein: assessed across 28 joints including the shoulder, elbow, wrist, MCP (1 through 5), PIP (1 through 5) and knee, with all 14 joints assessed for each side of the body. It is a composite score derived from examination of the 28 joints for swelling and tenderness, global assessment of pain and overall status using a VAS and a blood marker of inflammation (hsCRP).

    DAS28-CRP(4) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 TJC- tender joint count, SJC- swollen joint count, CRP- C reactive protein, GH - patient global health

  22. Minimal Disease Activity

    Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

    A psoriatic arthritis patient is defined as having a Minimal Disease Activity (MDA) response (Yes/No) when the patient meets at least 5 of the 7 following criteria:

    • tender joint count ≤1;
    • swollen joint count ≤1;
    • PASI score ≤1 or BSA ≤3%;
    • patient Arthritis Pain (VAS)

    ≤15 mm;

    • patient's global arthritis assessment (VAS) ≤20 mm;
    • HAQ-DI score ≤0.5;
    • tender entheseal points (using LEI) ≤1.
  23. Change From Baseline in Leeds Dactylitis Index (LDI)

    Time frame: week 4, week 12, and week 24

    tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)

    Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score

    Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45

    The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.

    Lower Leeds Dactylitis Index score represent better outcome.

  24. Change From Baseline in Leeds Dactylitis Index (LDI)

    Time frame: Week 52

    tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)

    Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score

    Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45

    The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.

    Lower Leeds Dactylitis Index score represent better outcome.

  25. Change From Baseline in Leeds Enthesitis Index (LEI)

    Time frame: week 4, week 12 and week 24

    The LEI examines tenderness at 6 sites:

    2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.

    Lower the score better is the outcome

  26. Change From Baseline in Leeds Enthesitis Index (LEI)

    Time frame: Week 52

    The LEI examines tenderness at 6 sites:

    2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.

    Lower the score better is the outcome

Sponsors and collaborators

Lead sponsor

Sun Pharmaceutical Industries Limited

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Dec 2, 2016
Registry last updated
Jan 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.